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available on the Mexican Formulary Catalog (naproxen/esomeprazole, NSAIDs 
group and celecoxib). Incremental cost-effectiveness ratio (ICER) was performed 
with two measures: Life Years without AE (LY) and Quality Adjusted Life Years 
(QALYs). The analysis was done from public perspective, only considered direct 
costs, and is reported in US dollars. RESULTS: Treatment with 
naproxen/esomeprazole versus NSAIDs represents an ICER of $318.85 for one 
year without AE; celecoxib had an ICER of $1,226.59, less effective than 
naproxen/esomeprazole. The ICER per QALY gain was $1,363.26 for 
naproxen/esomeprazole and $4,562.90 for celecoxib. Sensitivity analysis 
confirms the consistency of the results. CONCLUSIONS: Naproxen/esomeprazole 
FDC dominated celecoxib and NSAIDs. The use of naproxen/esomeprazole in the 
treatment of patients with OA at risk of developing GI AE is cost-effective and 
could be considered as the first option in an institutional setting.  
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Ronquest N1, Mladsi DM1, Hopley C2, Edgell ET3 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2DePuy UK, Leeds, UK, 3DePuy 
Orthopaedics, Inc., Warsaw, IN, USA  
OBJECTIVES: New Innovative Knee Implants (IKIs) have the potential to reduce 
patients' awareness of the artificial knee, increase their confidence in 
performing daily activities, and reduce problems leading to revisions compared 
with Contemporary Knee Implants (CKI). This study aimed to illustrate the 
expected economic value of a new IKI among osteoarthritis (OA) patients 
requiring total knee arthroplasty (TKA). METHODS: A Markov model was 
developed to explore the cost-effectiveness of the IKI compared with CKIs among 
OA patients undergoing TKA from a United States payer perspective. The model 
design distinguished between the IKI and CKIs in terms of functional status and 
implant survivorship. CKI survivorship was estimated using patient-level 
survivorship data with SIGMA fixed bearing knees from the United Kingdom 
National Joint Registry. To estimate IKI survivorship, the approach used by Suter 
et al. (2011) was adopted. Adjustments were made to the risk of revision for 
causes addressed in the design of the IKI, specifically, wear, loosening, pain, 
instability, patella maltracking, and stiffness. Costs and utilities associated with 
various health states were literature based. RESULTS: The model predicts that 
the IKI will reduce revisions by nearly 20% and that this improvement in 
survivorship will translate to economic savings. Additionally, independent of 
survivorship, improvements in patient functioning will result in economic value. 
The IKI is expected to be cost-neutral with improved health, when restricting the 
expected benefit to survivorship only, or to be a therapy that both improves 
health and reduces costs when functional improvements are also considered. 
CONCLUSIONS: Although TKA can be a successful intervention, there is still 
potential for IKIs to provide clinical and economic value. Further investigation to 
quantify the link between improvement in IKI design features and clinical 
outcomes is necessary to improve the understanding of potential IKI clinical and 
economic benefits.  
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OBJECTIVES: The aim of the study was to evaluate the cost-effectiveness of 
denosumab (60 mg every 6 months) in the treatment of postmenopausal 
osteoporosis (PMO) women in México at high risk of fractures and intolerant to 
oral bisphosphonates. METHODS: The study was conducted from the public 
payer perspective using the comparators of raloxifene (60 mg daily) and 
teriparatide (20 mcg daily). High risk was defined as having 2 of the following 3 
risk factors: Age ≥70 years, T-score ≤-3 or previous fracture. Life years gained 
(LYG) were the effectiveness measure used in the model. The model reported the 
weighted Incremental Cost-effectiveness Ratio (ICER) for 3 possible scenarios: 1) 
Age ≥70 years and T-score ≤-3, without previous fracture; 2) Age ≥ 70 years with 
previous fracture; 3) T-score ≤-3 with previous fracture. A Markov model was 
performed using a lifetime horizon and 5 years of treatment. The Diagnoses-
Related Groups costs reported by Mexican Institute for Social Security (IMSS) for 
Mexico were used for different types of fractures. A discount rate of 5% was used 
for costs and health outcomes. The costs were reported in 2011 Mexican pesos. 
RESULTS: According to the average results for the 3 scenarios, the costs are 
$199,546 pesos for raloxifene, $202,969 pesos for denosumab and $269,304 pesos 
for teriparatide. The incremental cost per LYG with denosumab in comparison 
with raloxifene is $42,775 Mexican pesos and $-941,995 Mexican pesos versus 
teriparatide. CONCLUSIONS: Denosumab is a cost-effective alternative versus 
raloxifene because the ICER is 22% below to 1 GDP per capita (local cost-
effectiveness threshold). Also, denosumab can be considered a cost-saving 
alternative versus teriparatide because it reduces costs and increases clinical 
benefits in the treatment of PMO women in Mexico at high risk for fracture and 
intolerant to oral BPs.  
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OBJECTIVES: Systemic idiopathic juvenile arthritis (sJIA) is a subtype of juvenile 
idiopathic arthritis (JIA), characterized by systemic manifestations of disease in 
addition to arthritis leading to significant patient morbidity, caregiver burden, 
and health care costs. The TENDER study demonstrated that treatment with 
tocilizumab resulted in a significant benefit over placebo. The objective of this 
study is to determine the cost-effectiveness of tocilizumab with or without 
methotrexate compared to placebo with methotrexate for the treatment of sJIA. 
METHODS: A Markov model was developed to capture time spent by patients in 
various health states, which included: no American College of Rheumatology 
(ACR) Response (uncontrolled), ACR Response 30, 50, 70, 90, and Death. Results 
were reported as incremental cost per additional quality adjusted life-years 
(QALY) gained, over a 16-year period (from age 2-18 years). Transition 
probabilities were derived from the TENDER study and published literature. The 
base case analysis focused on direct medical costs only from the perspective of 
the Canadian Ministry of Health (MoH). A second analysis was conducted from 
the societal perspective. Cost data were obtained from a variety of sources and 
reported as 2011 Canadian Dollars. A 5% discount rate was applied to both costs 
and patient outcomes. Multiple sensitivity analyses were undertaken to test the 
robustness of the model. RESULTS: From the MoH perspective, tocilizumab with 
or without methotrexate had an incremental cost-utility ratio (ICUR) of $69,787 
per additional QALY gained compared to placebo with methotrexate. The 
treatment with tocilizumab would be the dominant (less costly and more 
effective) treatment strategy from the societal perspective. Results were robust 
over a wide range of sensitivity analyses tested. CONCLUSIONS: Tocilizumab 
with or without methotrexate is a cost-effective strategy compared to placebo 
with methotrexate for patients with sJIA.  
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OBJECTIVES: This study determines the lifetime survival function, utility 
function and health care expenditure for 8 types of cancer, end-stage renal 
disease (ESRD) and rheumatoid arthritis (RA) stratified by gender and age in 
Taiwan, and provides data to estimate cost-per-QALY for comparison. 
METHODS: A total of 335,918 pathologically verified cancer patients registered in 
the National Cancer Registry of Taiwan during 1998-2007, and 125,277 ESRD 
patients and 39, 455 RA patients registered under “catastrophic illnesses” were 
included. All of them were followed until the end of 2010 to obtain the survival 
function, which were further extrapolated to lifetime based on a semi-
parametric method using the age- and sex-matched referents simulated from 
the life tables of the National Vital Statistics of Taiwan. The survival functions 
were adjusted using an EQ-5D utility value derived from a convenience sample of 
8,421 patients to estimate quality-adjusted life expectancies (QALE). The monthly 
health care expenditures attributable to different cancers, ESRD and RA were 
collected from the reimbursement database of the National Health Insurance 
(NHI). These values were multiplied by the corresponding survival probabilities 
to calculate the lifetime health care expenditure after adjusting consumer price 
indices for different calendar year up to 2010 and assumed a 3% discount rate 
later on. RESULTS: ESRD had the highest life-time health care expenditure and 
cost-per-QALY, followed by RA and cancers, which is 16,933 to 17,851 U.S. dollars 
(USD) of cost-per QALY, or about one GDP (gross domestic products) of Taiwan. 
Of the 8 different cancers studied, the lung cancer, esophagus cancer and liver 
cancer had the highest cost-per-QALY. There appears a trend of shorter life 
expectancy or QALY associated with higher cost-per-QALY. CONCLUSIONS: Such 
estimates of cost-effectiveness are an essential part on the consideration to 
accommodate new health technology in cancer and other chronic diseases 
control, including prevention.  
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ASSOCIATION BETWEEN RITUXIMAB ADHERENCE AND ORAL 
GLUCOCORTICOID USE IN RHEUMATOID ARTHRITIS PATIENTS WITH PRIOR 
EXPOSURE TO ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY  
Johnston SS1, Kamath T2, Shi N3, Fowler R1, Chu BC4, Reiss W2 
1Truven Health Analytics, Washington, DC, USA, 2Genentech, South San Francisco, CA, USA, 
3Truven Health Analytics, Cambridge, MA, USA, 4Truven Health Analytics, Santa Barbara, CA, 
USA  
OBJECTIVES: Oral glucocorticoids (OGCs) have therapeutic benefits in 
rheumatoid arthritis (RA), but can produce adverse effects. This study examined 
the association between rituximab adherence and OGC use reduction in RA 
patients. METHODS: Retrospective study using a large U.S. claims database. 
Patients included for study had initiated rituximab between March 1, 2006-March 
31, 2011 (initiation date=index), had pre-index exposure to anti-tumor necrosis 
factor-alpha (anti-TNF) therapy, were aged ≥18 years, had a medical claim with a 
diagnosis code for RA (ICD-9-CM 714.0x) between January 1, 2004-March 31, 2011, 
were continuously enrolled for 12 months before and ≥270 days after index, and 
had OGC use ≤30 days before index. Patients were excluded if they had medical 
claims with diagnosis codes for non-RA indications of biologic disease modifying 
antirheumatic drugs (BDMARDs). Based on rituximab infusion services dates and 
recommended 6-month reinfusions, rituximab exposure periods were 
constructed to start upon index and end at the first occurrence of switch to a 
